Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation - No Study Results Posted

Evaluation of Weekly Subcutaneous Biotinylated Idraparinux Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation (BOREALIS-AF)

This study is currently recruiting participants.

Study NCT00580216 Information provided by Sanofi-Aventis

First Received: December 21, 2007 Last Updated: October 19, 2009 History of Changes

No Study Results Posted for this Study

About Study Results Reporting

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	March 2011
Estimated Primary Completion Date:	March 2011 (Final data collection date for primary outcome measure)